Patient-Reported Symptoms and Quality of Life: A Real-World Survey of Patients With Muscle Invasive Bladder Cancer
Author(s)
Jens Bedke, Prof. Dr.1, Anthony Eccleston, MSc2, Julia Brinkmann, MD MBA3, Abin Koshy, PharmD4, Jane Chang, MPH4, Neil Milloy, BA5, Laure Manuel, MSc5, Jacob Skilling, BSc5, Emilia Biondi, MSci5, Elliott Brown, MRes5, Caitlin Ford, BSc5, Yair Lotan, Prof.6.
1Department of Urology and Transplantation Surgery, Ev Mayr-Stihl Cancer Center, Stuttgart, Germany, 2Pfizer Inc, Surrey, United Kingdom, 3Pfizer Inc, Berlin, Germany, 4Pfizer Inc, New York, NY, USA, 5Adelphi Real World, Bollington, United Kingdom, 6Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
1Department of Urology and Transplantation Surgery, Ev Mayr-Stihl Cancer Center, Stuttgart, Germany, 2Pfizer Inc, Surrey, United Kingdom, 3Pfizer Inc, Berlin, Germany, 4Pfizer Inc, New York, NY, USA, 5Adelphi Real World, Bollington, United Kingdom, 6Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Presentation Documents
OBJECTIVES: To understand patients’ perspectives on health-related quality of life (HRQoL) using patient-reported outcome measures (PROMs) in patients with muscle invasive bladder cancer (MIBC) who received radical cystectomy (RC; group A) compared to those who refused/were ineligible for RC (group B).
METHODS: Data were drawn from the Adelphi Real World MIBC Disease Specific Programme™, a cross-sectional survey, with retrospective data collection of physicians and patients in France, Germany, Spain, Italy and the United Kingdom from December 2023 to May 2024. Patients voluntarily completed a patient self-completion form.
PROMs included: EQ-5D-5L (German Tariff: range, 1 [full health] to 0 [death]), EORTC-QLQ-C30 and MIBC module (EORTC-QLQ-BLM30) where scores range from 0-100, with higher scores indicating higher functioning while for symptomology greater symptom severity. Analyses were descriptive.
RESULTS: Overall, 396 MIBC patients reported data (n=208; group A and n=188; group B). At data collection mean (standard deviation [SD]) patient age was 70.8 (8.21), and 23% were T0, N0 (31%; group A vs. 15%; group B).
Mean (SD) days between diagnosis and data collection was 268.4 (161.35; group A) vs 199.1 (144.89; group B).
Mean (SD) EQ-5D-5L index was 0.83 (0.16; group A) vs 0.75 (0.22; group B).
Mean (SD) EORTC global health status score was 56.5 (18.66; group A) vs 51.4 (19.71; group B). Mean (SD) symptoms score for fatigue was 37.0 (24.97; group A) vs 45.6 (26.89; group B).
Using the EORTC-QLQ-BLM30, mean (SD) scores in group A vs group B were 30.7 (27.77) vs 23.8 (25.69) for abdominal bloating and flatulence, 28.7 (25.44) vs 28.1 (25.53) for sexual functioning, and 46.3 (24.39) vs 49.2 (26.54) for future perspective, respectively.
CONCLUSIONS: MIBC impacts patients HRQoL. Patient-reported HRQoL burden is especially high among patients who did not receive a RC, highlighting the need for novel bladder-sparing therapies which reduce symptoms and improve HRQoL.
METHODS: Data were drawn from the Adelphi Real World MIBC Disease Specific Programme™, a cross-sectional survey, with retrospective data collection of physicians and patients in France, Germany, Spain, Italy and the United Kingdom from December 2023 to May 2024. Patients voluntarily completed a patient self-completion form.
PROMs included: EQ-5D-5L (German Tariff: range, 1 [full health] to 0 [death]), EORTC-QLQ-C30 and MIBC module (EORTC-QLQ-BLM30) where scores range from 0-100, with higher scores indicating higher functioning while for symptomology greater symptom severity. Analyses were descriptive.
RESULTS: Overall, 396 MIBC patients reported data (n=208; group A and n=188; group B). At data collection mean (standard deviation [SD]) patient age was 70.8 (8.21), and 23% were T0, N0 (31%; group A vs. 15%; group B).
Mean (SD) days between diagnosis and data collection was 268.4 (161.35; group A) vs 199.1 (144.89; group B).
Mean (SD) EQ-5D-5L index was 0.83 (0.16; group A) vs 0.75 (0.22; group B).
Mean (SD) EORTC global health status score was 56.5 (18.66; group A) vs 51.4 (19.71; group B). Mean (SD) symptoms score for fatigue was 37.0 (24.97; group A) vs 45.6 (26.89; group B).
Using the EORTC-QLQ-BLM30, mean (SD) scores in group A vs group B were 30.7 (27.77) vs 23.8 (25.69) for abdominal bloating and flatulence, 28.7 (25.44) vs 28.1 (25.53) for sexual functioning, and 46.3 (24.39) vs 49.2 (26.54) for future perspective, respectively.
CONCLUSIONS: MIBC impacts patients HRQoL. Patient-reported HRQoL burden is especially high among patients who did not receive a RC, highlighting the need for novel bladder-sparing therapies which reduce symptoms and improve HRQoL.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
RWD12
Topic
Real World Data & Information Systems
Disease
SDC: Oncology